Patent: WO 2013/046163


Is a product based on liposomes derivatized with a Bombesin peptide analogue, and loaded with Doxorubicin for therapy of cancers expressing bombesin GRP receptors, particularly used in Ovarian and/or Prostate cancer therapy.


Patent 2016: 102016000005812 (Pending)

A Kit for a simple and fast preparation of liposomal doxorubicin in which liposomes are externally modified with a targeting peptide.